Modulation of HMGB1, PRF1, TRAIL, and M-CSF after TARGIT-IORT in breast-conserving surgery: defining a unique acute immune landscape
{{output}}
Background: Targeted intraoperative radiotherapy (TARGIT-IORT) delivers a single high-dose boost to the tumor bed during breast-conserving surgery (BCS) and is now recommended only within clinical trials or registries. Its acute ... ...
